Medical Condition News

RSS

GSK receives FDA approval for Lamictal XR to treat partial seizures

GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.

26 Apr 2011

Study: 80% of blacks more likely to spend all personal finances for cancer care

People in minority groups, especially black Americans, are more willing than their white counterparts to exhaust their personal financial resources to prolong life after being diagnosed with lung or colorectal cancer, according to a University of Alabama at Birmingham study published April 26, 2011, online in Cancer, the journal of the American Cancer Society.

26 Apr 2011

People who travel extensively for business have high rates of health risk factors

People who travel extensively for business have increased rates of poor health and health risk factors, including obesity and high blood pressure, reports a study in the April Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

26 Apr 2011

Scientists develop new low cost test for acute pancreatitis

A new low cost test for acute pancreatitis that gets results much faster than existing tests has been developed by scientists at The University of Texas at Austin.

26 Apr 2011

Frequent social activity may prevent or delay cognitive decline in old age

If you want to keep your brain healthy, it turns out that visiting friends, attending parties, and even going to church might be just as good for you as crossword puzzles.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

SI-BONE receives FDA approval for updated iFuse Implant System

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint announced the U.S. Food and Drug Administration approved a major modification to the existing product label.

26 Apr 2011

Red pepper consumption can help manage appetite

Spicing up your daily diet with some red pepper can curb appetite, especially for those who don't normally eat the popular spice, according to research from Purdue University.

26 Apr 2011

UC Davis professor receives $4.8 million federal grant for child obesity study

UC Davis professor Adela de la Torre, a national expert on Chicano and Latino health issues, today received a five-year, $4.8 million federal grant to discover the best ways to help Mexican-heritage children in California maintain healthy weights.

26 Apr 2011

Corticosteroid creams do not cause skin thinning: Study

According to a new study, long term use of steroid creams to treat children with the skin condition known as eczema doesn't cause any major negative side effects.

25 Apr 2011

Aussies avoiding regular dental check-ups: Report

According to a new report, the annual visit to the dentist is becoming a luxury for many Australians and almost 40 per cent of the population does not go for regular check-ups.

25 Apr 2011

Abbott’s mental health plan draws support and surprise

The mental health proposals by Tony Abbott may have been deemed fiscally irresponsible by the federal government but they have won backing from experts of the Australian Medical Association.

25 Apr 2011

A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV).

25 Apr 2011

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology.

25 Apr 2011

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.

25 Apr 2011

Adults with PTSD and history of childhood trauma have shorter telomeres

Adults with post-traumatic stress disorder and a history of childhood trauma had significantly shorter telomere length than those with PTSD but without childhood trauma, in a study by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

25 Apr 2011

Simple, obvious and obscure ways to keep minds sharp and brains healthy

From a glance at the magazine stands, Americans appear obsessed with losing weight, cutting their cardiac risks and seeking to improve their odds against cancer. But where's the focus on brain health?

25 Apr 2011